Lazertinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 156 publications
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Journal: Journal of medical economics
Published: April 13, 2026
Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.
Journal: Investigational new drugs
Published: March 16, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 26, 2026
Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.
Journal: Journal of thoracic disease
Published: February 25, 2026
Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.
Journal: Frontiers in oncology
Published: February 02, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 23, 2026
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 19, 2026
The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability.
Journal: Exploration of targeted anti-tumor therapy
Published: December 30, 2025
Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
Journal: Cancer research and treatment
Published: December 23, 2025
Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib.
Journal: Current oncology (Toronto, Ont.)
Published: December 21, 2025
Last Updated: 06/30/2026